Aim: To improve curability of radiotherapy in HNSCC patients identified by hypoxic FAZA-PET scanning
Prospective phase II study aiming to improve the outcome in hypoxic resistent patients identified by FAZA-PET. Inclusion: Patients must fulfill the following: Positive hypoxic FAZA-PET Scanning (as described in DAHANCA 24 - see citation) Stage III-IV, Squamous cell carcinoma of the larynx, pharynx or oral cavity (HPVneg (oropharynx) Indication for hyperfractionated accelerated radiotherapy with concommitant cis-platin and nimorazole
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
Department of Experimental Clinical Oncology, Aarhus University Hospital
Aarhus, Denmark
RECRUITINGLoco-regional failure
loco-regional failure defined as persistent or recurrent disease in tumor and/or regional lymphnode sites (within the radiotherapy treated volume). The primary endpoint did not include the effect of a successful procedure with salvage surgery (no primary neck dissection was allowed).
Time frame: Year 3
Overall survival
Death from all causes
Time frame: Year 3
Acute radiation related morbidity
Time frame: Month 3
Late radiation related morbidity
Time frame: Year 3
Disease-specific death
Disease-specific death is defined as death from or with the cancer in question;
Time frame: Year 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.